|
1
|
Gautam M, Singh S, Aggarwal M, Sharma MK,
Dang S and Gabrani R: Glioblastoma multiforme; drug resistance
& combination therapy. Front Anti Cancer Drug Discovery Volume.
10:1112019. View Article : Google Scholar
|
|
2
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. New Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke J, Butowski N and Chang S: Recent
advances in therapy for glioblastoma. Arch Neurol. 67:279–283.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Chen L, Bao Z, Li S, You G, Yan W,
Shi Z, Liu Y, Yang P, Zhang W, et al: Inhibition of STAT3 reverses
alkylator resistance through modulation of the AKT and β-catenin
signaling pathways. Oncol Rep. 26:1173–1180. 2011.PubMed/NCBI
|
|
5
|
Sinnberg T, Menzel M, Ewerth D, Sauer B,
Schwarz M, Schaller M, Garbe C and Schittek B: β-Catenin signaling
increases during melanoma progression and promotes tumor cell
survival and chemoresistance. PLoS One. 6:e234292011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mrugala MM and Chamberlain MC: Mechanisms
of disease: Temozolomide and glioblastoma-look to the future. Nat
Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agnihotri S, Gajadhar AS, Ternamian C,
Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M,
Carlson BL, et al: Alkylpurine-DNA-N-Glycosylase confers resistance
to temozolomide in xenograft models of glioblastoma multiforme and
is associated with poor survival in patients. J Clin Invest.
122:253–266. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motomura K, Natsume A and Wakabayashi T:
Intravenous administration of temozolomide as a useful alternative
over oral treatment with temozolomide capsules in patients with
gliomas. J Neuroncol. 106:209–211. 2012. View Article : Google Scholar
|
|
9
|
Cahill DP, Levine KK, Betensky RA, Codd
PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR,
Curry WT, et al: Loss of the mismatch repair protein MSH6 in human
glioblastomas is associated with tumor progression during
temozolomide treatment. Clin Cancer Res. 13:2038–2045. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yip S, Miao J, Cahill DP, Iafrate AJ,
Aldape K, Nutt CL and Louis DN: MSH6 mutations arise in
glioblastomas during temozolomide therapy and mediate temozolomide
resistance. Clin Cancer Res. 15:4622–4629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Avgeropoulos NG and Batchelor TT: New
treatment strategies for malignant gliomas. Oncologist. 4:209–224.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu K, Zhang Z, Pei H, Wang H, Li L and Xia
Q: FoxO3a induces temozolomide resistance in glioblastoma cells via
the regulation of β-catenin nuclear accumulation. Oncol Rep.
37:2391–2397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peifer M, Rauskolb C, Williams M,
Riggleman B and Wieschaus E: The segment polarity gene armadillo
interacts with the wingless signaling pathway in both embryonic and
adult pattern formation. Development. 111:1029–1043.
1991.PubMed/NCBI
|
|
14
|
Noordermeer J, Klingensmith J, Perrimon N
and Nusse R: Dishevelled and armadillo act in the wingless
signalling pathway in drosophila. Nature. 367:80–83. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Chen H, Chen Y and Cheng X:
Significance of beta-catenin and Cyclin D1 express in glioma. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 25:1010–1012. 2009.(In Chinese).
PubMed/NCBI
|
|
16
|
Liu X, Wang L, Zhao S, Ji X, Luo Y and
Ling F: β-Catenin overexpression in malignant glioma and its role
in proliferation and apoptosis in glioblastma cells. Med Oncol.
28:608–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu C, Tu Y, Sun X, Jiang J, Jin X, Bo X,
Li Z, Bian A, Wang X, Liu D, et al: Wnt/Beta-Catenin pathway in
human glioma: Expression pattern and clinical/prognostic
correlations. Clin Exp Med. 11:105–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pukkila M, Virtaniemi J, Kumpulainen E,
Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT and Kosma VM:
Nuclear beta catenin expression is related to unfavourable outcome
in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin
Pathol. 54:42–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elzagheid A, Buhmeida A, Korkeila E,
Collan Y, Syrjänen K and Pyrhönen S: Nuclear beta-catenin
expression as a prognostic factor in advanced colorectal carcinoma.
World J Gastroenterol. 14:3866–3871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang CL, Liu D, Ishikawa S, Nakashima T,
Nakashima N, Yokomise H, Kadota K and Ueno M: Wnt1 overexpression
promotes tumour progression in non-small cell lung cancer. Eur J
Cancer. 44:2680–2688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noda T, Nagano H, Takemasa I, Yoshioka S,
Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, et
al: Activation of wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Accili D and Arden KC: FoxOs at the
crossroads of cellular metabolism, differentiation, and
transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myatt SS and Lam EWF: The emerging roles
of forkhead box (Fox) proteins in cancer. Nat Rev Cancer.
7:847–859. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu
LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al:
Constitutively nuclear FOXO3a localization predicts poor survival
and promotes akt phosphorylation in breast cancer. PLoS One.
5:e122932010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Storz P, Döppler H, Copland JA, Simpson KJ
and Toker A: FOXO3a promotes tumor cell invasion through the
induction of matrix metalloproteinases. Mol Cell Biol.
29:4906–4917. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu K, Pei H, Zhang Z, Dong S, Fu RJ, Wang
WM and Wang H: FoxO3a mediates glioma cell invasion by regulating
MMP9 expression. Oncol Rep. 36:3044–3050. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun J, Wei H, Yi J, Chen J and Tian B:
Human umbilical cord mesenchymal stem cells restore imatinib and
doxorubicin sensitivity in drug-resistant chronic myeloid leukemia
cells. Int J Clin Exp Med. 11:2142–2147. 2018.
|
|
28
|
Aldonza MBD, Hong JY and Lee SK:
Paclitaxel-Resistant cancer cell-derived secretomes elicit
ABCB1-associated docetaxel cross-resistance and escape from
apoptosis through FOXO3a-driven glycolytic regulation. Exp Mol Med.
49:e2862017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dwivedi A, Slater SC and George SJ: MMP-9
and-12 cause N-cadherin shedding and thereby beta-catenin
signalling and vascular smooth muscle cell proliferation.
Cardiovasc Res. 81:178–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tenbaum SP, Ordóñez-Morán P, Puig I,
Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert
JD, Mendizabal L, et al: β-Catenin confers resistance to PI3K and
AKT inhibitors and subverts FOXO3a to promote metastasis in colon
cancer. Nat Med. 18:8922012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kahlert U, Nikkhah G and Maciaczyk J:
Epithelial-To-Mesenchymal (-like) transition as a relevant
molecular event in malignant gliomas. Cancer Lett. 331:131–138.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laios A, Mohamed BM, Kelly L, Flavin R,
Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, et al:
Pre-Treatment of platinum resistant ovarian cancer cells with an
MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as
determined by high content screening. Int J Mol Sci. 14:2085–2103.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fiore E, Fusco C, Romero P and Stamenkovic
I: Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically
cleaves ICAM-1 and participates in tumor cell resistance to natural
killer cell-mediated cytotoxicity. Oncogene. 21:5213–5223. 2002.
View Article : Google Scholar : PubMed/NCBI
|
